Olmat 40 H Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil 40 mg and Hydrochlorothiazide 12.5 mg. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby preventing vasoconstriction and aldosterone secretion, leading to vasodilation and reduction in blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to decreased blood volume and peripheral resistance. The combination of these two agents provides complementary mechanisms to achieve effective blood pressure control in patients with essential hypertension, especially those who do not respond adequately to monotherapy. Olmat 40 H is indicated for the treatment of hypertension to reduce the risk of cardiovascular events such as stroke and myocardial infarction. It is important to monitor electrolytes, renal function, and blood pressure regularly during therapy. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in pregnancy and patients with hypersensitivity to any component. Adverse effects may include dizziness, hypotension, electrolyte imbalance, and gastrointestinal disturbances. Patient adherence and lifestyle modifications are essential for optimal therapeutic outcomes.